Handok signs contract with Roche Korea for the sale of osteoporosis drug “Bonviva” in Korea

–Handok will be in charge of the marketing and sales of Bonviva tablets and injections and Bonviva Plus in Korea.

–Bonviva is an osteoporosis drug for postmenopausal women used worldwide. It has excellent efficacy and is highly tolerable.

Handok (Chairman and CEO: Kim Young-jin) signed a contract with Korea Roche Co., Ltd. (General Manager: Mike Crichton) for the sale of the osteoporosis drug “Bonviva” (Ibandronate sodium) and “Bonviva Plus” (Ibandronate sodium, cholecalciferol) in Korea. According to the contract, Handok will be in charge of the marketing and sales of the drug in Korea.

Bonviva is available in two forms: a tablet administered once a month or an intravenous injection given every three months. The results of research conducted on female postmenopausal osteoporosis patients show that the monthly administration of Bonviva tablets (150 milligrams) is more effective than daily administration (2.5 milligrams), and patients’ tolerance is comparable. The Bonviva Plus tablet is a mixture of the therapeutic component of ibandronate sodium and Vitamin D (cholecalciferol) and is administered once a month. It improves not only bone density but also serum Vitamin D levels in postmenopausal women.

Speaking about the agreement, Handok Chairman Kim Young-jin said, “I am very pleased to have strengthened Handok’s portfolio of osteoporosis drugs with the addition of Bonviva. Handok will make continuous efforts to help osteoporosis patients increase the quality of their lives.”

Roche Korea General Manager Mike Crichton announced, “Bonviva is an osteoporosis drug used worldwide that features excellent efficacy and is highly tolerable. Through our affiliation with Handok, which has excellent marketing capabilities and extensive experience, Bonviva will be able to reach patients more readily.”